Thus, equilibrium between two pathways—PD-L1-induced down-regulation of sTNFR2 and inflammation-induced up-regulation of sTNFR2 levels—may eventually dictate the equilibrium between the protective and tumor-promoting activities of TNFR2 in TNBC. The gene discussed is CD274; the disease is neoplasm.